134 related articles for article (PubMed ID: 28624622)
21. Protein expression of DNA damage repair proteins dictates response to topoisomerase and PARP inhibitors in triple-negative breast cancer.
Boerner JL; Nechiporchik N; Mueller KL; Polin L; Heilbrun L; Boerner SA; Zoratti GL; Stark K; LoRusso PM; Burger A
PLoS One; 2015; 10(3):e0119614. PubMed ID: 25774912
[TBL] [Abstract][Full Text] [Related]
22. 3-chloromethylene-6-fluorothiochroman-4-one, A novel DNA Topoisomerase poison.
Wang Y; Chen J; Shen R; Yang C; Ma Z; Liu Y
Pak J Pharm Sci; 2016 Nov; 29(6 Suppl):2377-2383. PubMed ID: 28167481
[TBL] [Abstract][Full Text] [Related]
23. PARP inhibition potentiates the cytotoxic activity of C-1305, a selective inhibitor of topoisomerase II, in human BRCA1-positive breast cancer cells.
Węsierska-Gądek J; Zulehner N; Ferk F; Składanowski A; Komina O; Maurer M
Biochem Pharmacol; 2012 Nov; 84(10):1318-31. PubMed ID: 22906755
[TBL] [Abstract][Full Text] [Related]
24. A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.
Yu CC; Pan SL; Chao SW; Liu SP; Hsu JL; Yang YC; Li TK; Huang WJ; Guh JH
Biochem Pharmacol; 2014 Aug; 90(3):320-30. PubMed ID: 24915421
[TBL] [Abstract][Full Text] [Related]
25. Synthesis, crystal structure and antiproliferative activity of Cu(II) nalidixic acid-DACH conjugate: comparative in vitro DNA/RNA binding profile, cleavage activity and molecular docking studies.
Arjmand F; Yousuf I; Hadda Tb; Toupet L
Eur J Med Chem; 2014 Jun; 81():76-88. PubMed ID: 24826817
[TBL] [Abstract][Full Text] [Related]
26. Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders.
Henning RJ; Bourgeois M; Harbison RD
Cardiovasc Toxicol; 2018 Dec; 18(6):493-506. PubMed ID: 29968072
[TBL] [Abstract][Full Text] [Related]
27. N-fused imidazoles as novel anticancer agents that inhibit catalytic activity of topoisomerase IIα and induce apoptosis in G1/S phase.
Baviskar AT; Madaan C; Preet R; Mohapatra P; Jain V; Agarwal A; Guchhait SK; Kundu CN; Banerjee UC; Bharatam PV
J Med Chem; 2011 Jul; 54(14):5013-30. PubMed ID: 21644529
[TBL] [Abstract][Full Text] [Related]
28. Decreased nucleotide excision repair activity and alterations of topoisomerase IIalpha are associated with the in vivo resistance of a P388 leukemia subline to F11782, a novel catalytic inhibitor of topoisomerases I and II.
Kruczynski A; Barret JM; Van Hille B; Chansard N; Astruc J; Menon Y; Duchier C; Créancier L; Hill BT
Clin Cancer Res; 2004 May; 10(9):3156-68. PubMed ID: 15131057
[TBL] [Abstract][Full Text] [Related]
29. Cationic and Neutral N-Heterocyclic Carbene Gold(I) Complexes: Cytotoxicity, NCI-60 Screening, Cellular Uptake, Inhibition of Mammalian Thioredoxin Reductase, and Reactive Oxygen Species Formation.
Zhang C; Hemmert C; Gornitzka H; Cuvillier O; Zhang M; Sun RW
ChemMedChem; 2018 Jun; 13(12):1218-1229. PubMed ID: 29603648
[TBL] [Abstract][Full Text] [Related]
30. Olaparib and temozolomide in desmoplastic small round cell tumors: a promising combination in vitro and in vivo.
van Erp AEM; van Houdt L; Hillebrandt-Roeffen MHS; van Bree NFHN; Flucke UE; Mentzel T; Shipley J; Desar IME; Fleuren EDG; Versleijen-Jonkers YMH; van der Graaf WTA
J Cancer Res Clin Oncol; 2020 Jul; 146(7):1659-1670. PubMed ID: 32279088
[TBL] [Abstract][Full Text] [Related]
31. Reactive oxygen species-mediated synergistic and preferential induction of cell death and reduction of clonogenic resistance in breast cancer cells by combined cisplatin and FK228.
Pluchino LA; Choudhary S; Wang HC
Cancer Lett; 2016 Oct; 381(1):124-32. PubMed ID: 27477899
[TBL] [Abstract][Full Text] [Related]
32. A novel epoxypropoxy flavonoid derivative and topoisomerase II inhibitor, MHY336, induces apoptosis in prostate cancer cells.
Patra N; De U; Kang JA; Kim JM; Ahn MY; Lee J; Jung JH; Chung HY; Moon HR; Kim HS
Eur J Pharmacol; 2011 May; 658(2-3):98-107. PubMed ID: 21376033
[TBL] [Abstract][Full Text] [Related]
33. Mortaparib, a novel dual inhibitor of mortalin and PARP1, is a potential drug candidate for ovarian and cervical cancers.
Putri JF; Bhargava P; Dhanjal JK; Yaguchi T; Sundar D; Kaul SC; Wadhwa R
J Exp Clin Cancer Res; 2019 Dec; 38(1):499. PubMed ID: 31856867
[TBL] [Abstract][Full Text] [Related]
34. Pyrroloquinolinone-based dual topoisomerase I/II inhibitor.
Dalla Via L; Marzaro G; Ferrarese A; Gia O; Chilin A
Eur J Med Chem; 2014 Apr; 77():103-9. PubMed ID: 24631729
[TBL] [Abstract][Full Text] [Related]
35. Clarifying the Mechanism of Copper(II) α-(N)-Heterocyclic Thiosemicarbazone Complexes on DNA Topoisomerase IIα and IIβ.
Keck JM; Conner JD; Wilson JT; Jiang X; Lisic EC; Deweese JE
Chem Res Toxicol; 2019 Oct; 32(10):2135-2143. PubMed ID: 31512855
[TBL] [Abstract][Full Text] [Related]
36. Quercetin-3-O-glucoside induces human DNA topoisomerase II inhibition, cell cycle arrest and apoptosis in hepatocellular carcinoma cells.
Sudan S; Rupasinghe HP
Anticancer Res; 2014 Apr; 34(4):1691-9. PubMed ID: 24692698
[TBL] [Abstract][Full Text] [Related]
37. In vitro and in silico assessment of DNA interaction, topoisomerase I and II inhibition properties of chrysosplenetin.
Şöhretoğlu D; Barut B; Sari S; Özel A; Arroo R
Int J Biol Macromol; 2020 Nov; 163():1053-1059. PubMed ID: 32673727
[TBL] [Abstract][Full Text] [Related]
38. Synthesis and biological evaluation of benzo[a]phenazine derivatives as a dual inhibitor of topoisomerase I and II.
Zhuo ST; Li CY; Hu MH; Chen SB; Yao PF; Huang SL; Ou TM; Tan JH; An LK; Li D; Gu LQ; Huang ZS
Org Biomol Chem; 2013 Jun; 11(24):3989-4005. PubMed ID: 23657605
[TBL] [Abstract][Full Text] [Related]
39. Enhanced cytotoxicity of silver complexes bearing bidentate N-heterocyclic carbene ligands.
Monteiro DC; Phillips RM; Crossley BD; Fielden J; Willans CE
Dalton Trans; 2012 Apr; 41(13):3720-5. PubMed ID: 22327273
[TBL] [Abstract][Full Text] [Related]
40. DNA topoisomerases as targets for the anticancer drug TAS-103: primary cellular target and DNA cleavage enhancement.
Byl JA; Fortune JM; Burden DA; Nitiss JL; Utsugi T; Yamada Y; Osheroff N
Biochemistry; 1999 Nov; 38(47):15573-9. PubMed ID: 10569941
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
